[go: up one dir, main page]

Allen et al., 2010 - Google Patents

QL-24. EXPLORING RELATIONSHIPS OF EXECUTIVE CONTROL AND INDEPENDENT FUNCTION: OBSERVATIONS OF COMPENSATION BEHAVIORS IN …

Allen et al., 2010

View PDF
Document ID
4828542335938398993
Author
Allen D
Carlson B
Neelon V
Giovanello K
Publication year
Publication venue
Neuro-Oncology

External Links

Snippet

CONTEXT: Activation of the epidermal growth factor receptor (EGFR) pathway has been implicated with mediating treatment resistance in glioblastoma multiformes (GBMs). OBJECTIVES: To identify a subset of GBM patients who may benefit from the addition of …
Continue reading at academic.oup.com (PDF) (other versions)

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00Radiation therapy
    • A61N5/10X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy

Similar Documents

Publication Publication Date Title
Brown et al. A prospective phase II randomized trial of proton radiotherapy vs intensity-modulated radiotherapy for patients with newly diagnosed glioblastoma
Goda et al. Hippocampal radiotherapy dose constraints for predicting long-term neurocognitive outcomes: mature data from a prospective trial in young patients with brain tumors
Cassier et al. Long-term clinical activity, safety and patient-reported quality of life for emactuzumab-treated patients with diffuse-type tenosynovial giant-cell tumour
Canter et al. Radiographic and histologic response to neoadjuvant radiotherapy in patients with soft tissue sarcoma
Lee et al. EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases
Bronk et al. Analysis of pseudoprogression after proton or photon therapy of 99 patients with low grade and anaplastic glioma
Herrera et al. The role of PET/CT in cervical cancer
Jalali et al. Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma
Dearnaley et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects
van Baardwijk et al. Time trends in the maximal uptake of FDG on PET scan during thoracic radiotherapy. A prospective study in locally advanced non-small cell lung cancer (NSCLC) patients
Wolff et al. Treatment of recurrent diffuse intrinsic pontine glioma: the MD Anderson Cancer Center experience
Monjazeb et al. A phase I dose escalation study of hypofractionated IMRT field-in-field boost for newly diagnosed glioblastoma multiforme
Reddy et al. Prospective evaluation of health-related quality of life in patients with glioblastoma multiforme treated on a phase II trial of hypofractionated IMRT with temozolomide
Walbert et al. Recurrent high-grade glioma: a diagnostic and therapeutic challenge
Rutkowski et al. Pleomorphic xanthoastrocytoma with anaplastic features: retrospective case series
Kim et al. Long-term outcomes of fractionated stereotactic radiation therapy for pituitary adenomas at the BC Cancer Agency
Harat et al. Safety and efficacy of irradiation boost based on 18F-FET-PET in patients with newly diagnosed glioblastoma
Mochizuki et al. Precision medicine in pediatric neurooncology: a review
Khasraw et al. Bevacizumab for the treatment of high-grade glioma
You et al. Re-irradiation combined with bevacizumab for recurrent glioblastoma beyond bevacizumab failure: survival outcomes and prognostic factors
Levitt et al. Controversies in the management of brain metastases
Kowalchuk et al. Contemporary radiotherapy and radiosurgery techniques for refractory pituitary adenomas
McKenzie et al. Radiosurgery fractionation and post-treatment hemorrhage development for intact melanoma brain metastases
Jilla et al. Impact of various prognostic factors on survival in glioblastoma: tertiary care institutional experience
Kotecha et al. Multidisciplinary management strategies for recurrent brain metastasis after prior radiotherapy: An overview